羟氯喹在复发性妊娠丢失中的应用:来自法国前瞻性多中心登记研究的数据
该研究基于法国FALCO前瞻性多中心登记,评估有复发性妊娠丢失(RPL)史女性孕早期暴露羟氯喹(HCQ)后的妊娠结局。74名女性共100次妊娠中,62次在12周内终止,38次超过12周;
要点
- 有RPL史女性孕早期暴露HCQ后,62%妊娠在12周内终止。
- 既往流产次数是妊娠超过12周的唯一显著预测因素(调整OR=3.13)。
- 自身抗体阳性与妊娠超过12周无显著关联(P=0.63)。
核心结论
- 有RPL史女性孕早期暴露HCQ似乎不能预防后续流产,提示对母体免疫系统相关机制影响有限。
研究设计与样本
- FALCO登记为2017年建立的法国前瞻性多中心不育登记研究,纳入18至49岁、至少有3次早期流产(≤12孕周)的自发性RPL女性。
- 纳入登记中自发性妊娠且孕前或孕早期暴露HCQ者,排除同时暴露TNF抑制剂、IL-1/IL-2抑制剂、静脉免疫球蛋白和/或静脉脂肪乳输注的妊娠。
- 允许同时使用低剂量阿司匹林、低分子肝素、孕酮和/或泼尼松;所有患者接受推荐的RPL评估,妊娠后按法国推荐进行产科护理并前瞻性随访。
- 主要终点为妊娠持续超过12孕周,次要终点为活产。
主要发现
- 共评估74名女性的100次HCQ暴露妊娠,平均年龄34.2岁,既往流产中位数5次。
- 合并暴露:泼尼松78次(78%)、低剂量阿司匹林56次(56%)、低分子肝素41次(41%)。
- 62次(62%)妊娠在12孕周内终止,其余38次(38%)持续超过12孕周。
- 至少一种自身抗体阳性且无卵巢储备减退者妊娠超过12周的比例为18/51(35.3%),无此类抗体者为18/45(40.0%),差异无统计学显著(P=0.63)。
关键数值与推荐
- 自身抗体阳性(抗核抗体滴度≥1:160、≥1种常规和/或非常规抗磷脂抗体阳性、和/或≥1种抗甲状腺抗体阳性)且无卵巢储备减退者妊娠超过12周为18/51(35.3%),无此类抗体者为18/45(40.0%),P=0.63。
临床怎么用
- 原文未据此给出推荐。
局限性
- 缺乏对照组。
- 部分患者RPL诊断流程数据不完整。
- 无法获取子宫内膜活检结果。
- 缺乏父亲年龄和行为因素信息。
- 因此并非所有潜在混杂因素均被考虑。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
STUDY QUESTION: What are the outcomes of pregnancies exposed to hydroxychloroquine (HCQ) in women with a history of recurrent pregnancy loss (RPL), and what factors predict the course of these pregnancies beyond the first trimester? SUMMARY ANSWER: In our cohort of pregnancies in women with a history of RPL exposed to HCQ early in pregnancy, we found that the only factor determining the success of these pregnancies was the number of previous miscarriages. WHAT IS KNOWN ALREADY: Dysregulation of the maternal immune system plays a role in RPL. HCQ, with its dual immunomodulating and vascular protective effects, is a potential treatment for unexplained RPL. STUDY DESIGN, SIZE, DURATION: The FALCO (Facteurs de récidive précoce des fausses couches) registry is an ongoing French multicenter infertility registry established in 2017 that includes women (aged from 18 to 49 years) with a history of spontaneous RPL (at least three early miscarriages (≤12 weeks of gestation (WG)) recruited from several university hospitals. PARTICIPANTS/MATERIALS, SETTING, METHODS: Spontaneous pregnancies enrolled in the FALCO registry with an exposure to HCQ (before conception or at the start of pregnancy) were included. Pregnancies concomitantly exposed to tumor necrosis factor inhibitors, interleukin-1 and -2 inhibitors, intravenous immunoglobulin, and/or intravenous intralipid infusion, were excluded. Concomitant treatment with low-dose aspirin (LDA), low-molecular weight heparin (LMWH), progesterone, and/or prednisone was allowed. All patients underwent the recommended evaluations for investigating RPL. Those who became pregnant received obstetric care in accordance with French recommendations and were followed prospectively. The main endpoint was the occurrence of a pregnancy continuing beyond 12 WG, and the secondary endpoint was the occurrence of a live birth. MAIN RESULTS AND THE ROLE OF CHANCE: One hundred pregnancies with HCQ exposure in 74 women were assessed. The mean age of the women was 34.2 years, and the median number of previous miscarriages was 5. Concomitant exposure was reported in 78 (78%) pregnancies for prednisone, 56 (56%) pregnancies for LDA, and 41 (41%) pregnancies for LMWH. Sixty-two (62%) pregnancies ended within 12 WG, the other 38 (38%) continuing beyond 12 WG. The risk of experiencing an additional early spontaneous miscarriage increased with the number of previous miscarriages, but not with age. The distributions of anomalies identified in RPL investigations and of exposure to other drugs were similar between pregnancies lasting ≤12 WG and those continuing beyond 12WG. The incidence of pregnancies progressing beyond 12 WG was not higher among pregnancies with at least one positive autoantibody (Ab) (i.e. antinuclear Ab titer ≥1:160, ≥1 positive conventional and/or non-conventional antiphospholipid Ab, and/or positive results for ≥1 antithyroid Ab) without diminished ovarian reserve (18/51, 35.3%) than among those without such autoantibody (18/45, 40.0%) (P = 0.63). Multivariate analysis showed that having ≤4 prior miscarriages was the only factor significantly predictive for achieving a pregnancy > 12 WG, after adjustment for age and duration of HCQ use prior to conception (adjusted odds ratio (OR) = 3.13 [1.31-7.83], P = 0.01). LIMITATIONS, REASONS FOR CAUTION: Our study has limitations, including the absence of a control group, incomplete data for the diagnostic procedure for RPL in some patients, and the unavailability of results from endometrial biopsies, as well as information about paternal age and behavioral factors. Consequently, not all potential confounding factors could be considered. WIDER IMPLICATIONS OF THE FINDINGS: Exposure to HCQ in early pregnancy for women with a history of RPL does not seem to prevent further miscarriages, suggesting limited impact on mechanisms related to the maternal immune system. STUDY FUNDING/COMPETING INTEREST(S): The research received no specific funding, and the authors declare no competing interests. TRIAL REGISTRATION NUMBER: clinicaltrial.gov NCT05557201.
引用
- Dernoncourt A, Hedhli K, Abisror N, et al. Hydroxychloroquine in recurrent pregnancy loss: data from a French prospective multicenter registry. Hum Reprod. 2024. PMID: 38942601. doi:10.1093/humrep/deae146
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。